ANGO shares rise in pre-market after surpassing Q3 earnings estimates, though gross margin declines
AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of $0.07 for Q3 fiscal 2026, exceeding analyst estimates, and saw an 8.9% increase in revenue to $78.4 million. The growth was driven by strong sales in its Med Tech segment, particularly Auryon, mechanical thrombectomy products, and NanoKnife. Despite these positive results and an updated fiscal 2026 guidance with increased net sales projections, the company experienced a decline in pro forma gross margin and continues to report adjusted operating losses.
ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down
AngioDynamics, Inc. (ANGO) reported an adjusted loss per share narrower than expected for Q3 fiscal 2026, with revenues increasing 8.9% year-over-year to $78.4 million, beating analyst estimates. Despite strong growth in its Med Tech and Med Device businesses, the company's pro forma gross margin declined. AngioDynamics revised its fiscal 2026 guidance upward for net sales and Med Tech/Med Device revenue growth, while narrowing its projected adjusted loss per share.
Canaccord Genuity Group Has Lowered Expectations for AngioDynamics (NASDAQ:ANGO) Stock Price
Canaccord Genuity Group reduced its price target for AngioDynamics (NASDAQ:ANGO) from $18 to $16 but maintained a "buy" rating, indicating a potential upside of 62% from the current price. Analyst ratings for AngioDynamics are mixed, with a consensus "Hold" rating and an average target price of $18.67. The company's stock trades at $9.86, has a market cap of $406 million, and despite beating earnings and revenue estimates last quarter, remains unprofitable with a forecasted -$0.37 EPS for the year.
Freedom Broker initiates AngioDynamics stock coverage with buy rating
Freedom Broker has initiated coverage on AngioDynamics Inc. (NASDAQ: ANGO) with a buy rating and a $16.00 price target, representing a 59% upside, citing an improving growth profile and momentum in specific product lines. Despite the positive outlook, the company is not expected to be profitable this year. This latest analyst action follows AngioDynamics' strong fiscal Q3 2026 earnings report, where it surpassed EPS and revenue expectations, leading Canaccord to reaffirm its Buy rating while slightly adjusting its price target.
AngioDynamics Earnings Call Highlights Med Tech Momentum
AngioDynamics (ANGO) reported strong Q3 earnings with an 8.9% year-over-year revenue increase, driven by significant growth in its Med Tech segment. The company raised its full-year revenue and adjusted EBITDA guidance, signaling confidence in its strategic pivot towards higher-growth, higher-margin therapies like Auryon, AlphaVac, AngioVac, and NanoKnife. Despite facing headwinds from tariffs, manufacturing transitions, and higher operating costs impacting margins and cash flow, the management highlighted robust commercial momentum and accelerated adoption across its key Med Tech platforms.
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2026 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO) reported strong Q3 2026 earnings, leading them to raise full-year guidance for the third consecutive quarter. The company saw impressive growth in its Med Tech segment, particularly with Auryon and Mechanical Thrombectomy products, indicating their strategy to focus on high-margin markets is succeeding. Despite challenges like tariffs and inflation, AngioDynamics maintained profitability and expects continued growth, especially from AlphaVac, while also addressing leadership transition and the passing of a key R&D leader.
AngioDynamics Q3: Revenue $78.4M, Loss per Share $(0.19)
AngioDynamics reported third-quarter net sales of $78.4 million, an 8.9% increase year-over-year, alongside a net loss of $8.1 million, or $(0.19) per diluted share. The company's operating loss was $(12.951) million, with a gross margin of 52.9% of sales. Growth was primarily driven by the Med Tech segment and U.S. direct sales, with positive momentum in key product lines despite an expanded net loss.
AngioDynamics Inc (NASDAQ:ANGO) Beats Q3 Earnings Estimates and Raises Full-Year Guidance
AngioDynamics Inc (NASDAQ:ANGO) reported strong fiscal Q3 2026 results, surpassing analyst expectations for revenue and significantly beating on earnings per share. The company's Med Tech segment demonstrated robust growth, leading management to raise its full-year fiscal 2026 guidance for net sales, Med Tech growth, Adjusted EBITDA, and Adjusted EPS, despite a negative pre-market market reaction. This performance indicates a successful pivot towards high-growth technology platforms and strong underlying business momentum.
AngioDynamics, Inc. Q3 2026 Earnings Call Summary
AngioDynamics, Inc. reported strong Q3 2026 results driven by a strategic shift to high-margin Med Tech markets, with Auryon and Mechanical Thrombectomy portfolios showing double-digit growth. The company raised its full-year net sales and adjusted EBITDA guidance, anticipating continued expansion for products like NanoKnife internationally and the AlphaReturn Blood Management System. Despite facing headwinds from tariffs and manufacturing transition costs, AngioDynamics expects to generate substantial cash flow in Q4 and maintain its growth trajectory.
AngioDynamics (NASDAQ:ANGO) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS
AngioDynamics (NASDAQ:ANGO) reported strong Q3 earnings, beating analyst estimates by $0.13 EPS with revenue of $78.4 million, an 8.9% year-over-year increase. The company also raised its FY26 net sales guidance and adjusted EBITDA, driven by significant growth in its MedTech products like Auryon, AlphaVac, and NanoKnife. Despite these positive results, the company faces challenges with gross margin decline due to tariffs and manufacturing transitions, potentially leading to slightly negative FY26 cash flow.
AngioDynamics, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:ANGO) 2026-04-02
AngioDynamics, Inc. (NASDAQ: ANGO) has released its Q3 2026 earnings call presentation. This slide deck accompanies the company's financial results discussion for the third quarter of 2026. The presentation provides details related to their performance for the quarter.
AngioDynamics (ANGO) Posts Third Quarter Loss, Surpasses Revenue Expectations
AngioDynamics (ANGO) reported a smaller-than-expected quarterly loss of $0.07 per share, beating the Zacks Consensus Estimate of $0.11 per share. The company also surpassed revenue expectations, generating $78.42 million against an estimate of $72 million for the quarter ending February 2026. Despite a 7% decline in shares year-to-date, AngioDynamics has consistently outperformed EPS and revenue forecasts over the past four quarters.
[8-K] ANGIODYNAMICS INC Reports Material Event
AngioDynamics Inc. (NASDAQ: ANGO) reported its fiscal Q3 2026 results, showing net sales of $78.4 million, an 8.9% year-over-year increase, driven by strong growth in its Med Tech segment. Despite continued GAAP net losses, the company raised its full-year 2026 guidance for net sales, Med Tech growth, adjusted EBITDA, and adjusted EPS, reflecting confidence in its strategic execution. The report also highlights the company's debt-free balance sheet with $37.8 million in cash, though a planned increase in inventory due to vendor sterilization shutdowns may result in slightly negative full-year cash flow.
AngioDynamics: Fiscal Q3 Earnings Snapshot
AngioDynamics Inc. (ANGO) reported a loss of $8.1 million, or 19 cents per share, in its fiscal third quarter. Adjusted losses were 7 cents per share, with the medical device maker posting revenue of $78.4 million. The company expects full-year results to range from a loss of 30 cents to 23 cents per share, with revenue between $313.5 million and $315.5 million.
AngioDynamics beats estimates on Med Tech strength, stock up nearly 3%
AngioDynamics Inc. (NASDAQ:ANGO) reported strong fiscal Q3 2026 results, surpassing analyst expectations with an adjusted loss per share of -$0.07 and revenue of $78.4 million. The company's Med Tech segment saw significant growth, particularly in its mechanical thrombectomy portfolio, leading to a 2.85% rise in pre-market trading. AngioDynamics also raised its fiscal 2026 revenue guidance for the third consecutive quarter, reflecting continued strong performance.
AngioDynamics (NASDAQ:ANGO) Downgraded to Hold Rating by Zacks Research
AngioDynamics (NASDAQ:ANGO) has been downgraded from a "strong-buy" to a "hold" rating by Zacks Research, with other firms also trimming their ratings. The stock's consensus rating is now "Hold" with a target price of $19.33. Shares opened at $11.37, showing a market capitalization of $468.67 million and a negative P/E of -16.97.
AngioDynamics investors can watch Needham conference webcast April 14
AngioDynamics (NASDAQ: ANGO) announced that its management team will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 8:45 a.m. (ET). A live webcast of the presentation will be available for investors to access through the "Investors" section of the company's website. The presentation will also be available for replay after the event.
Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Decreases By 18.0%
AngioDynamics (NASDAQ:ANGO) experienced an 18.0% decrease in short interest in March, totaling 1,784,550 shares as of March 13th. This represents about 4.6% of the company's shares shorted and a days-to-cover ratio of 6.3 days. Shares opened at $10.90, and institutional investors own 89.43% of the stock, while analysts rate it a "Moderate Buy" with a $19.33 price target.
Quant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lag
This article provides a quantitative snapshot of stock recommendations, highlighting J. Jill and AngioDynamics as leading strong buys. Conversely, INmune Bio and Terrestrial Energy are noted as lagging. It offers a quick overview of current market sentiment based on quantitative analysis.
AngioDynamics, Inc. (NASDAQ:ANGO) Receives Average Recommendation of "Moderate Buy" from Brokerages
AngioDynamics, Inc. (NASDAQ:ANGO) has received a consensus "Moderate Buy" rating from five brokerages, with an average 1-year target price of $19.33. The medical technology company's shares opened at $10.90, and institutional investors own approximately 89.43% of the stock. Recent analyst activities include ratings changes from Wall Street Zen, Weiss Ratings, and Zacks Research.
How (ANGO) Movements Inform Risk Allocation Models
This article analyzes Angiodynamics Inc. (NASDAQ: ANGO) using AI models, identifying a near-term strong sentiment influencing a mid-term neutrality towards a long-term positive bias. It highlights a significant 50.0:1 risk-reward setup, targeting a 14.4% gain with minimal risk, and outlines three distinct trading strategies for different risk profiles. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
Vanguard disaggregates holdings; reports 0 shares in AngioDynamics (ANGO)
The Vanguard Group has filed an amended passive investment disclosure (SCHEDULE 13G/A) for AngioDynamics Inc (ANGO), reporting 0 shares beneficially owned, representing 0% of the class. This change is due to an internal realignment effective January 12, 2026, where Vanguard and certain subsidiaries will now report holdings separately. The filing clarifies that this does not indicate a sale but rather a disaggregation of holdings, with subsequent filings from Vanguard subsidiaries potentially showing redistributed shares.
AngioDynamics (ANGO) Expected to Announce Quarterly Earnings on Thursday
AngioDynamics (NASDAQ:ANGO) is scheduled to release its Q3 2026 earnings before market open on Thursday, April 2nd. Analysts forecast an EPS of ($0.11) and revenue of $76.77 million. The stock was trading up approximately 5.6% and institutional ownership stands at a high 89.43%.
AngioDynamics launches 2026 summer internships for driven students
AngioDynamics has announced its 2026 Summer Internship Program, inviting applications from students for positions in Latham, New York, Queensbury, New York, and online. The program aims to provide hands-on professional experience to ambitious individuals seeking to make an impact within the organization. This initiative is part of AngioDynamics' ongoing focus on workforce and product growth, complementing recent announcements about cardiovascular sales recruitment and product demonstrations.
Port Catheter Infection Lawsuit Claims SmartPort Defects Caused Sepsis, Pulmonary Embolism
A lawsuit has been filed against AngioDynamics by Malia Hookano, alleging that a defective SmartPort catheter caused her to develop sepsis and a pulmonary embolism. The complaint claims that AngioDynamics failed to improve the SmartPort's design despite numerous adverse event reports shortly after its market release. This lawsuit joins hundreds of other similar claims consolidated in a multidistrict litigation, with bellwether trials expected to begin to assess jury responses to the evidence.
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) reported a narrower-than-expected loss in Q4 but missed revenue estimates. The company posted a loss of $0.02 per share, beating the Zacks Consensus Estimate of a $0.05 loss, while revenues of $82.5 million slightly missed the consensus estimate. Despite the revenue miss, the reported revenue was 0.82% higher than the prior-year quarter.
AngioDynamics schedules April 2 earnings call before market open
AngioDynamics (NASDAQ: ANGO) announced it will release its third-quarter fiscal year 2026 financial results before the market opens on Thursday, April 2, 2026. The company's management will host a conference call at 8:00 AM ET on the same day to discuss these results. Investors can access the webcast and replay information through the "Investors" section of AngioDynamics' website.
H.C. Wainwright Reaffirms Buy Rating on AngioDynamics (ANGO) After Strong Q1 Performance
H.C. Wainwright has reiterated its Buy rating on AngioDynamics (ANGO) following the company's robust Q1 performance, which saw beats on revenue and adjusted EPS, led by growth in key product lines. The firm slightly increased its price target to $18, reflecting strong growth catalysts such as the AlphaVac product and ongoing improvements in gross margins. This positive outlook signals confidence in AngioDynamics' continued financial and operational strength.
AngioDynamics launches Mini Stick MAX Coaxial Microintroducer Kit targeting improved patient outcomes
AngioDynamics has launched its new Mini Stick MAX Coaxial Microintroducer Kit, designed to enhance procedural accuracy and patient comfort during minimally invasive vascular procedures. This release builds on the company's recent efforts to strengthen its cardiovascular sales presence and its continued focus on advancing microintroducer technology. The kit's unveiling emphasizes AngioDynamics' commitment to improving patient outcomes and procedural efficacy.
AngioDynamics Stock Forms Death Cross, Signaling Bearish Trend Ahead
AngioDynamics, Inc. has experienced a Death Cross, indicating a potential bearish trend. The stock has seen a year-to-date decline of 17.45%, significantly underperforming the S&P 500. This technical event, coupled with bearish daily moving averages, suggests caution for investors.
AngioDynamics, Inc. $ANGO Shares Acquired by Divisadero Street Capital Management LP
Divisadero Street Capital Management LP substantially increased its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 8.3% in the third quarter, now holding 3,678,125 shares valued at approximately $41.09 million. This makes AngioDynamics the fund's 14th-largest holding. Despite mixed analyst ratings, the stock holds a "Moderate Buy" consensus with a significant upside implied by the average price target of $19.33 compared to its recent opening of $10.60.
Chemotherapy Injection Port Lawsuit Blames AngioDynamics SmartPort for Wrongful Death
A lawsuit has been filed against AngioDynamics, blaming its SmartPort chemotherapy injection port for the wrongful death of Nancy Whittemore. The family alleges that the device's design led to an infection that caused her death in April 2024, just months after implantation. This complaint joins nearly 350 other AngioDynamics port catheter lawsuits consolidated in multidistrict litigation, all alleging defective design and manufacturing causing issues like fractures, migration, and infections.
AngioDynamics at Leerink Conference: Strategic Shift to Tech-Driven Growth By Investing.com
AngioDynamics is strategically shifting its focus from commodity-based products to technology-driven markets in cardiovascular and interventional oncology. CEO Jim Clemmer highlighted the growth of platforms like Auryon for peripheral arterial disease, NanoKnife for prostate cancer, and AlphaVac for pulmonary embolism. The company is investing in R&D and sales force expansion, aiming for long-term growth and market penetration despite challenges like consistent payment coverage for NanoKnife.
How Angiodynamics Inc. (ANGO) Affects Rotational Strategy Timing
This article analyzes Angiodynamics Inc. (ANGO) using AI models to provide trading strategies. It highlights a weak near-term sentiment but strong long-term projections, indicating a mid-channel oscillation pattern. The analysis offers specific entry, target, and stop-loss levels for position trading, momentum breakouts, and risk hedging, based on multi-timeframe signal analysis.
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
AngioDynamics, Inc. (NASDAQ: ANGO) announced that its President and CEO, Jim Clemmer, will present at the Leerink Partners Global Healthcare Conference on March 9, 2026, at 1:40 p.m. ET. AngioDynamics is a medical technology company focused on vascular health and cancer treatment. A live webcast and replay of the presentation will be available on the company's website.
Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Decreases By 17.6%
Short interest in AngioDynamics, Inc. (NASDAQ:ANGO) fell by 17.6% in February, totaling 1,699,336 shares, representing 4.4% of shares sold short with a short-interest ratio of 3.8 days. Institutional investors hold approximately 89.43% of the stock, with several firms increasing their positions in Q4. Analysts maintain a "Moderate Buy" rating with an average target price of $19.33, suggesting significant upside from its current price of $11.36.
ANGO - Angiodynamics Latest Stock News & Market Updates
This page provides the latest news and insights on AngioDynamics (ANGO) stock, a medical technology company specializing in vascular interventions and oncology. It highlights company announcements on product platforms like Auryon and NanoKnife, regulatory milestones, clinical studies, and quarterly financial results. The news stream offers investors insights into product performance, clinical evidence, regulatory progress, and the company’s strategic focus on Med Tech growth.
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
AngioDynamics, Inc. (NASDAQ: ANGO) announced that its President and CEO, Jim Clemmer, will present at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 1:40 p.m. ET. A live webcast of the presentation will be available on the company's website in the "Investors" section, with a replay accessible afterward. AngioDynamics is a medical technology company focused on vascular health and cancer treatment options.
Hear AngioDynamics CEO Jim Clemmer live at Leerink healthcare conference
AngioDynamics (NASDAQ: ANGO) President and CEO, Jim Clemmer, will present at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 1:40 p.m. ET. A live webcast of the presentation will be available on the company's website. AngioDynamics specializes in medical technology for vascular systems, cancer treatment, and patient quality of life.
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
AngioDynamics, a medical technology company, announced that its President and CEO, Jim Clemmer, will present at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 1:40 p.m. ET. A live webcast and replay of the presentation will be available on the company's website. AngioDynamics focuses on restoring healthy blood flow, expanding cancer treatment options, and improving patient quality of life.
ANGO Expands NanoKnife in Europe for Multi-Organ Tumor Ablation
AngioDynamics (ANGO) has announced expanded indications for its NanoKnife System in Europe, broadening its use for soft tissue tumor ablation in the liver, pancreas, kidney, and prostate. This expansion is expected to drive significant growth for ANGO, as it targets challenging tumors and reinforces the system's utility in a market where Europe accounts for a substantial share of global irreversible electroporation (IRE) procedures. The company also plans to launch the LIVER-IRE Global Registry to further support clinical adoption and evidence generation for liver tumor treatment.
(ANGO) and the Role of Price-Sensitive Allocations
This article discusses Angiodynamics Inc. (NASDAQ: ANGO) and its price-sensitive allocations. It highlights a near-term neutral sentiment with underlying mid and long-term strength, noting an exceptional risk-reward setup. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
The CEO, President & Director of AngioDynamics, Inc. (NASDAQ:ANGO), James Clemmer, Just Bought 3.5% More Shares
James Clemmer, the CEO, President & Director of AngioDynamics, Inc. (NASDAQ:ANGO), recently purchased US$228k worth of the company's stock, increasing his holding by 3.5%. This marks the largest insider purchase in the last year, suggesting confidence in the company's future despite it having reported a loss. Overall, insiders have been net buyers over the past year, and their significant ownership aligns their interests with those of other shareholders.
Merit Medical buys two dialysis catheter lines for $132.5M combined
Merit Medical recently acquired two dialysis catheter product lines for a combined $132.5 million, expanding its offerings in the dialysis market. The company purchased dialysis catheters and a sealant system from AngioDynamics for $100 million and a catheter system from Bluegrass Vascular Technologies for $32.5 million. Analysts view these acquisitions as complementary to Merit's existing dialysis and biopsy products, projecting an additional $30 million in annual revenue and positive impact on non-GAAP EPS.
AngioDynamics expands European indications for NanoKnife system By Investing.com
AngioDynamics (NASDAQ:ANGO) has announced an expansion of the European indications for its NanoKnife System, now including soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, specifically for intermediate-risk prostate cancer patients. This move aims to strengthen the company's presence in the European medical technology market by increasing access to its irreversible electroporation (IRE) technology for various oncologic applications. The company also plans to launch the LIVER-IRE Global Registry to support clinical adoption and evidence development.
New tumor option in liver, pancreas, kidney as NanoKnife use widens in Europe
AngioDynamics (NASDAQ: ANGO) has announced expanded European indications for its NanoKnife System, allowing its use for soft tissue ablation in tumors of the liver, pancreas, kidney, and prostate, including intermediate-risk prostate cancer. This expansion increases physician access to the NanoKnife System's irreversible electroporation (IRE) technology for treating difficult-to-resect tumors or those near critical structures. The company will also initiate the LIVER-IRE Global Registry in collaboration with the University of Manchester to further evaluate outcomes for liver tumors.
Bastion Asset Management Inc. Buys 304,960 Shares of AngioDynamics, Inc. $ANGO
Bastion Asset Management Inc. significantly increased its stake in medical instruments supplier AngioDynamics, Inc. by 31.8% in Q3, purchasing 304,960 shares to hold 1,264,003 shares. This makes AngioDynamics its largest holding, valued at $13.44 million and representing 7.7% of Bastion's portfolio. Other institutional investors have also adjusted their holdings in AngioDynamics, which currently trades near $10.97 with a "Moderate Buy" consensus rating and a target price of $19.33.
Responsive Playbooks and the ANGO Inflection
This article analyzes Angiodynamics Inc. (NASDAQ: ANGO) using AI models, identifying strong near-term sentiment with a potential mid-term neutrality and long-term positive bias. It presents three distinct trading strategies—position, momentum breakout, and risk hedging—alongside multi-timeframe signal analysis for various risk profiles. The report highlights an exceptional 50.3:1 risk-reward short setup.
Essex Investment Management Co. LLC Increases Holdings in AngioDynamics, Inc. $ANGO
Essex Investment Management Co. LLC significantly increased its stake in AngioDynamics, Inc. by 41.9% in the third quarter of 2025, now holding 327,396 shares valued at $3.657 million. Despite mixed analyst ratings, with an average "Moderate Buy" and target price of $19.33, institutional investors collectively own 89.43% of AngioDynamics' stock. The medical instruments supplier's shares currently trade around $10.67, with a market capitalization of $439.82 million.
AngioDynamics, Inc. (NASDAQ:ANGO) Given Consensus Rating of "Moderate Buy" by Analysts
AngioDynamics, Inc. (NASDAQ:ANGO) has received a consensus "Moderate Buy" rating from five research firms, with an average 12-month price target of $19.33. Institutional investors hold 89.43% of the stock, with several firms increasing their stakes, notably Divisadero Street Capital Management LP. The company, a medical technology firm, currently has a market capitalization of $435.3 million and a negative P/E ratio.
